Enzo Biochem Inc. (ENZ) Scheduled to Post Quarterly Earnings on Friday
Enzo Biochem Inc. (NYSE:ENZ) will be issuing its Q416 quarterly earnings data on Friday, October 14th.
Enzo Biochem Inc. (NYSE:ENZ) opened at 5.09 on Thursday. The stock’s 50 day moving average is $5.36 and its 200 day moving average is $5.69. Enzo Biochem Inc. has a 12-month low of $3.48 and a 12-month high of $7.00. The stock has a market capitalization of $235.48 million, a PE ratio of 13.32 and a beta of 1.50.
Separately, Zacks Investment Research raised Enzo Biochem from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a report on Thursday, June 16th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/enzo-biochem-inc-enz-scheduled-to-post-quarterly-earnings-on-friday.html
Several large investors have recently bought and sold shares of the stock. Spark Investment Management LLC increased its stake in Enzo Biochem by 113.3% in the second quarter. Spark Investment Management LLC now owns 99,200 shares of the company’s stock valued at $592,000 after buying an additional 52,700 shares during the last quarter. Rhumbline Advisers purchased a new stake in Enzo Biochem during the second quarter valued at $233,000. Perceptive Advisors LLC purchased a new stake in Enzo Biochem during the second quarter valued at $401,000. Teachers Advisors Inc. purchased a new stake in Enzo Biochem during the second quarter valued at $373,000. Finally, American International Group Inc. increased its stake in Enzo Biochem by 2,184.6% in the second quarter. American International Group Inc. now owns 22,846 shares of the company’s stock valued at $136,000 after buying an additional 21,846 shares during the last quarter. 53.29% of the stock is owned by institutional investors and hedge funds.
About Enzo Biochem
Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.
Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.